AKBA
Price
$3.25
Change
-$0.04 (-1.22%)
Updated
Aug 15 closing price
Capitalization
861.72M
80 days until earnings call
RMTI
Price
$1.02
Change
-$0.03 (-2.86%)
Updated
Aug 15 closing price
Capitalization
34.94M
92 days until earnings call
Interact to see
Advertisement

AKBA vs RMTI

Header iconAKBA vs RMTI Comparison
Open Charts AKBA vs RMTIBanner chart's image
Akebia Therapeutics
Price$3.25
Change-$0.04 (-1.22%)
Volume$3.7M
Capitalization861.72M
Rockwell Medical
Price$1.02
Change-$0.03 (-2.86%)
Volume$123.67K
Capitalization34.94M
AKBA vs RMTI Comparison Chart in %
Loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RMTI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKBA vs. RMTI commentary
Aug 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a Hold and RMTI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 18, 2025
Stock price -- (AKBA: $3.25 vs. RMTI: $1.02)
Brand notoriety: AKBA and RMTI are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AKBA: 90% vs. RMTI: 41%
Market capitalization -- AKBA: $861.72M vs. RMTI: $34.94M
AKBA [@Pharmaceuticals: Generic] is valued at $861.72M. RMTI’s [@Pharmaceuticals: Generic] market capitalization is $34.94M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.74B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBA’s FA Score shows that 0 FA rating(s) are green whileRMTI’s FA Score has 0 green FA rating(s).

  • AKBA’s FA Score: 0 green, 5 red.
  • RMTI’s FA Score: 0 green, 5 red.
According to our system of comparison, RMTI is a better buy in the long-term than AKBA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBA’s TA Score shows that 4 TA indicator(s) are bullish while RMTI’s TA Score has 6 bullish TA indicator(s).

  • AKBA’s TA Score: 4 bullish, 6 bearish.
  • RMTI’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, RMTI is a better buy in the short-term than AKBA.

Price Growth

AKBA (@Pharmaceuticals: Generic) experienced а -4.97% price change this week, while RMTI (@Pharmaceuticals: Generic) price change was +5.89% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.

Reported Earning Dates

AKBA is expected to report earnings on Nov 06, 2025.

RMTI is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+6.26% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKBA($862M) has a higher market cap than RMTI($34.9M). AKBA YTD gains are higher at: 71.053 vs. RMTI (-50.000). AKBA has higher annual earnings (EBITDA): 6.59M vs. RMTI (3.01M). AKBA has more cash in the bank: 113M vs. RMTI (17.3M). RMTI has less debt than AKBA: RMTI (12.9M) vs AKBA (54.1M). AKBA has higher revenues than RMTI: AKBA (185M) vs RMTI (97.7M).
AKBARMTIAKBA / RMTI
Capitalization862M34.9M2,470%
EBITDA6.59M3.01M219%
Gain YTD71.053-50.000-142%
P/E RatioN/AN/A-
Revenue185M97.7M189%
Total Cash113M17.3M653%
Total Debt54.1M12.9M419%
FUNDAMENTALS RATINGS
AKBA vs RMTI: Fundamental Ratings
AKBA
RMTI
OUTLOOK RATING
1..100
5021
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
46
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10092
PRICE GROWTH RATING
1..100
4064
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a31

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RMTI's Valuation (46) in the Medical Specialties industry is somewhat better than the same rating for AKBA (80) in the Biotechnology industry. This means that RMTI’s stock grew somewhat faster than AKBA’s over the last 12 months.

RMTI's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as AKBA (100) in the Biotechnology industry. This means that RMTI’s stock grew similarly to AKBA’s over the last 12 months.

RMTI's SMR Rating (92) in the Medical Specialties industry is in the same range as AKBA (100) in the Biotechnology industry. This means that RMTI’s stock grew similarly to AKBA’s over the last 12 months.

AKBA's Price Growth Rating (40) in the Biotechnology industry is in the same range as RMTI (64) in the Medical Specialties industry. This means that AKBA’s stock grew similarly to RMTI’s over the last 12 months.

AKBA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as RMTI (100) in the Medical Specialties industry. This means that AKBA’s stock grew similarly to RMTI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKBARMTI
RSI
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 8 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
79%
Momentum
ODDS (%)
Bearish Trend 4 days ago
74%
Bullish Trend 4 days ago
90%
MACD
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 4 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
86%
Bullish Trend 4 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
88%
Advances
ODDS (%)
Bullish Trend 18 days ago
86%
Bullish Trend 5 days ago
86%
Declines
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 8 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
79%
Aroon
ODDS (%)
Bearish Trend 4 days ago
86%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RMTI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
COP95.33-0.32
-0.33%
ConocoPhillips
NEOG5.43-0.07
-1.27%
Neogen Corp
TG7.32-0.19
-2.53%
Tredegar Corp
OKUR2.53-0.14
-5.24%
OnKure Therapeutics Inc
AEIS151.40-10.49
-6.48%
Advanced Energy Industries

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with IPSC. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then IPSC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
-1.22%
IPSC - AKBA
39%
Loosely correlated
+2.15%
XERS - AKBA
39%
Loosely correlated
+5.21%
SYRE - AKBA
37%
Loosely correlated
+0.53%
KYMR - AKBA
36%
Loosely correlated
+2.60%
RXRX - AKBA
35%
Loosely correlated
+2.30%
More

RMTI and

Correlation & Price change

A.I.dvisor indicates that over the last year, RMTI has been loosely correlated with AVDL. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if RMTI jumps, then AVDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RMTI
1D Price
Change %
RMTI100%
-2.86%
AVDL - RMTI
34%
Loosely correlated
+1.41%
AKBA - RMTI
32%
Poorly correlated
-1.22%
EVOK - RMTI
31%
Poorly correlated
-0.39%
TKNO - RMTI
29%
Poorly correlated
-2.29%
EBS - RMTI
29%
Poorly correlated
+0.23%
More